Sarepta Therapeutics (SRPT) Cash from Operations (2010 - 2026)

Sarepta Therapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 202683000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 65.26% year-over-year to 202683000.0; the TTM figure through Mar 2026 stood at 175275000.0 (up 132.03% YoY), while the FY2025 annual figure was 205479000.0, changed 0.15% from the prior year.
• Cash from Operations for Q1 2026 stood at 202683000.0, down from 131206000.0 in the prior quarter.
• The five-year high for Cash from Operations was 261337000.0 in Q2 2025, with the low at 583437000.0 in Q1 2025.
• The 5-year median for Cash from Operations is 70699000.0 (2024), against an average of 84722823.53.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations tumbled 215.05% in 2022, then surged 1649.01% in 2025.
• Sarepta Therapeutics' Cash from Operations stood at 92392000.0 in 2022, then jumped by 40.84% to 54657000.0 in 2023, then soared by 268.41% to 92046000.0 in 2024, then surged by 42.54% to 131206000.0 in 2025, then plunged by 254.48% to 202683000.0 in 2026.
• Business Quant data shows SRPT's Cash from Operations at 202683000.0 in Q1 2026, 131206000.0 in Q4 2025, and 14585000.0 in Q3 2025.